Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-31 @ 11:41 AM
Study NCT ID:
NCT07398118
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-23
First Post:
2026-02-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003452', 'term': 'Cryosurgery'}, {'id': 'D017679', 'term': 'Cryotherapy'}], 'ancestors': [{'id': 'D055011', 'term': 'Ablation Techniques'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'SUPPORTIVE_CARE', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'This study uses a single-arm interventional model in which all participants undergo image-guided cryoablation as a one-time primary treatment. The study is designed to assess feasibility and safety in a selected population without randomisation or comparison to standard treatment.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 61}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-04-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-03', 'completionDateStruct': {'date': '2028-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-20', 'studyFirstSubmitDate': '2026-02-02', 'studyFirstSubmitQcDate': '2026-02-02', 'lastUpdatePostDateStruct': {'date': '2026-03-23', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-02-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Feasibility and acute safety of cryoablation', 'timeFrame': 'Up to 6 months after cryoablation', 'description': 'Feasibility is defined as successful completion of the cryoablation procedure as planned. Acute safety is assessed by the incidence of treatment-related adverse events following cryoablation, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\n\nAcute toxicity is graded according to the CTCAE v5.0 grading system, which classifies adverse events on an ordinal scale from Grade 1 (mild) to Grade 5 (death related to adverse event). The minimum score is Grade 1 and the maximum possible score is Grade 5. Higher grades indicate more severe toxicity (worse outcome).'}], 'secondaryOutcomes': [{'measure': 'Technical success of cryoablation', 'timeFrame': 'During the cryoablation procedure', 'description': 'Technical success is defined as correct placement of the cryoprobe(s) and completion of the planned freeze-thaw cycles resulting in complete coverage of the target tumour.'}, {'measure': 'Local tumour control', 'timeFrame': 'Up to 12 months after cryoablation', 'description': 'Local tumour control is defined as absence of residual or recurrent tumour at the treated site based on imaging and clinical follow-up.'}, {'measure': 'Patient-reported tolerance and quality of life', 'timeFrame': 'Baseline and up to 12 months after cryoablation', 'description': 'Participant-reported tolerance of the procedure and health-related quality of life assessed using validated questionnaires.'}, {'measure': 'Need for additional locoregional treatment', 'timeFrame': 'Up to 12 months after cryoablation', 'description': 'The proportion of participants requiring additional breast surgery or other locoregional treatment following cryoablation.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Cryoablation', 'Early-stage breast cancer', 'Non-curative', 'Elderly', 'Minimally invasive treatment', 'Breast tumour', 'Local tumour control', 'Feasibility study', 'Cryotherapy', 'Non-surgical treatment'], 'conditions': ['Breast Cancer Stage I', 'Breast Cancer Early Stage Breast Cancer (Stage 1-3)']}, 'descriptionModule': {'briefSummary': 'This study looks at a new way to treat early-stage breast cancer in older adults using a freezing technique called cryoablation.\n\nOlder adults with early-stage breast cancer are usually treated with surgery or primary endocrine therapy (hormone therapy). While these treatments can be effective, they may also be burdensome. Surgery can lead to pain, slow recovery, or complications, and primary endocrine therapy often requires long-term medication and may cause side effects or stop working over time. Cryoablation may offer a less invasive treatment option.\n\nThe goal of this study is to find out whether cryoablation can be safely and successfully used as the main treatment for older adults with early-stage breast cancer. Cryoablation destroys the tumour by freezing it. The procedure is performed through the skin using imaging guidance and does not involve surgical removal of the tumour.\n\nParticipants in this study are adults aged 70 years or older who have a small breast tumour that has not spread to the lymph nodes. All participants receive cryoablation as a single treatment.\n\nAfter the procedure, participants are followed closely. Researchers will collect information on side effects, recovery, whether additional treatment is needed, and how participants experience the treatment. Quality of life will also be assessed.\n\nThis study is carried out in several hospitals. All participants must give written informed consent before taking part. The results of this study may help determine whether cryoablation could be a safe and practical treatment option for older adults with early-stage breast cancer and guide future research.', 'detailedDescription': 'CRYO-1 is a multicentre, phase II, single-arm interventional feasibility study evaluating cryoablation as a primary treatment for older adults with early-stage breast cancer. The study includes participants aged 70 years or older with clinically node-negative (cT1N0), estrogen receptor-positive, HER2-negative invasive breast cancer.\n\nStandard treatment for this patient population consists of surgery or primary endocrine therapy. Although effective, both approaches may be associated with treatment burden in older adults. Surgical treatment may result in perioperative morbidity, while primary endocrine therapy requires prolonged treatment and may be associated with side effects and the development of endocrine resistance. Cryoablation is a minimally invasive, image-guided technique that induces tumour destruction by freezing and may reduce treatment burden in selected patients.\n\nIn this study, cryoablation is performed percutaneously under imaging guidance as a single procedure, without surgical excision of the primary tumour. The intervention is investigated as an alternative local treatment strategy in this selected population.\n\nThe primary objective of CRYO-1 is to assess feasibility and acute safety of cryoablation. Feasibility is defined by successful completion of the procedure, and safety is assessed by the incidence of treatment-related adverse events within three months, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\n\nSecondary objectives include technical success, need for additional locoregional treatment, early local tumour control, patient tolerance, and health-related quality of life. Exploratory objectives include longer-term oncologic outcomes and identification of factors associated with successful local control.\n\nCRYO-1 is an investigator-initiated study conducted across multiple hospitals. All participants provide written informed consent prior to enrolment. The study aims to generate prospective evidence on the feasibility and safety of cryoablation in older adults with early-stage breast cancer and to inform the design of future comparative or de-escalation studies.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '70 Years', 'genderBased': True, 'genderDescription': 'Females', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age ≥ 70 years\n* Histologically confirmed invasive breast cancer\n* Clinical stage cT1N0M0 based on mammography and ultrasound ER-positive, HER2-negative (IHC 0-1+ or 2+ with negative ISH), any PR status\n* Presence of concurrent DCIS is allowed if limited to \\<25% of the pre-NST biopsy, with no radiologic suspicion of an extensive component\n* Unifocal disease \\<2 cm, well visualized on ultrasound, with a minimum distance of ≥5 mm from the skin, nipple and thoracic wall\n* Ability and willingness to comply with project requirements\n* Preoperative endocrine therapy is allowed\n* Written informed consent given by the subject\n\nExclusion Criteria:\n\n* Pure DCIS lesions without invasive component\n* Extensive calcifications on imaging suggestive of widespread disease\n* Invasive lobular carcinoma (as assessed by IHC)\n* Triple-negative or HER2-positive subtype (defined as (IHC 3+ or ISH positive)\n* History of ipsilateral breast cancer or DCIS\n* Prior ipsilateral radiotherapy\n* Inability to communicate in Dutch or English language\n* Planned (e)migration or long-term stay abroad within one year after inclusion'}, 'identificationModule': {'nctId': 'NCT07398118', 'acronym': 'CRYO-1', 'briefTitle': 'CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer.', 'organization': {'class': 'OTHER', 'fullName': 'St. Antonius Hospital'}, 'officialTitle': 'Treatment of Elderly Patients With Early Stage Breast Cancer (CRYO-1): The Efficacy of Cryoablation In The Elderly - A Phase II Multicentre, Feasibility Study.', 'orgStudyIdInfo': {'id': 'R25.102'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cryoablation', 'description': 'Participants receive image-guided percutaneous cryoablation as a single primary treatment for early-stage breast cancer. Cryoablation is performed to destroy the tumour by freezing, without surgical excision of the primary tumour.', 'interventionNames': ['Procedure: Cryoablation / Cryotherapy']}], 'interventions': [{'name': 'Cryoablation / Cryotherapy', 'type': 'PROCEDURE', 'description': 'Cryoablation is performed as a percutaneous, image-guided procedure in which the breast tumour is destroyed by controlled freezing. One or more cryoprobes are placed into the tumour under imaging guidance, and freezing cycles are applied to achieve complete local tumour ablation. The procedure is performed as a single intervention without surgical excision of the primary tumour.', 'armGroupLabels': ['Cryoablation']}]}, 'contactsLocationsModule': {'locations': [{'zip': '6836 BH', 'city': 'Arnhem', 'state': 'Gelderland', 'country': 'Netherlands', 'contacts': [{'name': 'Ramon van Eekeren, MD, PhD', 'role': 'CONTACT', 'email': 'rvaneekeren@rijnstate.nl', 'phone': '+3164824542'}], 'facility': 'Rijnstate Hospital', 'geoPoint': {'lat': 51.98, 'lon': 5.91111}}, {'zip': '4818 CK', 'city': 'Breda', 'state': 'North Brabant', 'country': 'Netherlands', 'contacts': [{'name': 'Eliane CM Zeestraten, MD, PhD', 'role': 'CONTACT', 'email': 'EZeestraten@amphia.nl', 'phone': '+3123421369'}], 'facility': 'Amphia Hospital', 'geoPoint': {'lat': 51.58656, 'lon': 4.77596}}, {'zip': '1066 CX', 'city': 'Amsterdam', 'state': 'North Holland', 'country': 'Netherlands', 'contacts': [{'name': 'Frederieke van Duijnhoven, MD, PhD', 'role': 'CONTACT', 'email': 'f.v.duijnhoven@nki.nl', 'phone': '+31619874388'}], 'facility': 'Antoni van Leeuwenhoek - Nederlands Kanker Instituut', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}], 'centralContacts': [{'name': 'Iza Stekelenburg, MD', 'role': 'CONTACT', 'email': 'i.stekelenburg@antoniusziekenhuis.nl', 'phone': '+31657835198'}, {'name': 'Annemiek Doeksen, MD, PhD', 'role': 'CONTACT', 'email': 'a.doeksen@antoniusziekenhuis.nl', 'phone': '+31 616608284'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Individual participant data will not be shared because the dataset contains sensitive health information, and data sharing was not included in the informed consent or study protocol. Data will be analysed by the study team in accordance with applicable data protection regulations.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'St. Antonius Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Amphia Hospital', 'class': 'OTHER'}, {'name': 'Rijnstate Hospital', 'class': 'OTHER'}, {'name': 'Antoni van Leeuwenhoek Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Coordinating investigator', 'investigatorFullName': 'Iza Stekelenburg', 'investigatorAffiliation': 'St. Antonius Hospital'}}}}